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Abstract: As Yondelis joins the ranks of approved anti-cancer drugs, the benefit from exploring
the oceans’ biodiversity becomes clear. From marine toxins, relevant bioproducts can be obtained
due to their potential to interfere with specific pathways. We explored the cytotoxicity of toxin-
bearing secretions of the polychaete Eulalia onto a battery of normal and cancer human cell lines
and discovered that the cocktail of proteins is more toxic towards an ovarian cancer cell line (A2780).
The secretions’ main proteins were identified by proteomics and transcriptomics: 14-3-3 protein,
Hsp70, Rab3, Arylsulfatase B and serine protease, the latter two being known toxins. This mixture
of toxins induces cell-cycle arrest at G2/M phase after 3h exposure in A2780 cells and extrinsic
programmed cell death. These findings indicate that partial re-activation of the G2/M checkpoint,
which is inactivated in many cancer cells, can be partly reversed by the toxic mixture. Protein–protein
interaction networks partake in two cytotoxic effects: cell-cycle arrest with a link to RAB3C and
RAF1; and lytic activity of arylsulfatases. The discovery of both mechanisms indicates that venomous
mixtures may affect proliferating cells in a specific manner, highlighting the cocktails’ potential in the
fine-tuning of anti-cancer therapeutics targeting cell cycle and protein homeostasis.
Keywords: invertebrate; cytotoxicity; cancer; ovarian cancer; programmed cell death; cell cycle; toxin
1. Introduction
According to the World Health Organization (WHO), cancer is the second leading
cause of death globally. The numbers of cases are expected to rise every year despite
research on the subject being given top priority (reviewed by Das et al. [1]). From all
the types of cancers, breast and lung cancer are the leading causes of death, especially
in Europe, with prostate cancer following the rank [2]. Ovarian cancer is the deadliest
gynecological cancer in the world (see, for instance, [3]), in large part due to the late
diagnosis [4]. This type of cancer is in fact a range of neoplastic diseases that can have
different origins [5]. Research on new therapeutics for this disease is motivated by the
combed effect between genomic heterogeneity and cell resistance [6]. Moreover, finding a
suitable therapy with reduced effects on healthy tissue remains a challenge, leading to the
screening for novel anti-cancer compounds that offer more specific and less deleterious
strategies than traditional treatments.
Anti-cancer drugs developed from natural products such as toxins and alkaloids
nowadays represent 50% of all drugs that are used in chemotherapy [7]. After plants,
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fungi and bacteria have been leading the search for anti-cancer compounds, in addition
to novel antibiotics [7]. Some of the main targets of the quest for anti-cancer drugs are
signaling pathways that regulate cell survival and proliferation. Indeed, most research is
seemingly focused on the inhibition of specific protein kinases, such as Ras/Raf mitogen-
activated protein kinase (MEK) and extracellular signal-regulated kinase (ERK) signaling
pathways [8].
There is a growing awareness for the potential of the seas as a source of novel ther-
apeutic agents, in face of their immense biodiversity [7,9]. In fact, the number of marine
natural products explored for various biotechnological purposes has been increasing over
the past few years (see the review of Hu et al. [10] for a statistical appraisal on marine
bioprospecting). Accordingly, there is growing interest in the search for novel anti-cancer
compounds in marine life, benefitting from the constant advances in omics methods from
metabolomics to proteomics and transcriptomics [11]. With the exception of Yondelis
(trabectedin), an approved drug developed from a secondary metabolite (a quinoline) of
the tropical tunicate Ecteinascidia turbinata that competes with enzyme and transcription
factors that bind to DNA [12], most research has yet to be materialized into effect applica-
tions. Still, there are promising indications, from various marine animals as varied as the
bivalves, the Briozoa and the Porifera, on the effects of novel compounds on the inhibition
of DNA synthesis inhibition, RNA polymerase activity, activation of apoptosis and au-
tophagy and cell-cycle arrest in cancer cells [11,13–15]. In most cases, though, cancer cells
are merely used as a toxicological model, without a clear indication of mode-of-action.
From the Polychaeta, a little-explored but most promising group of marine animals for the
bioprospecting of novel bioproducts, there are growing indications for the existence of cy-
totoxic toxins. Among the most significant examples, we may find the toxin arenicin (from
Arenicola marina), nicomicin (from Nicomache minor), both peptidic in nature, and proteases
from Nereis, all presenting cytotoxicity towards cancer cell lines, seemingly with pro-
apoptotic effects (refer to Rodrigo and Costa [16] and references therein). The mechanisms
by which these substances exert noxious effects are not, however, fully understood, if at all.
In large part, this is due to constraints in handling the complex mixtures of which poisons,
venoms and toxungens are comprised, particularly in marine invertebrates, for whom
genomic resources are much reduced.
Recently, we disclosed the secretion of toxins by an intertidal Polychaeta, Eulalia sp.,
whose toxins, secreted by specialized cells in the eversible pharynx, are delivered to its prey
using mucus as a vehicle with the purpose of immobilization and cytolysis by means yet
unknown [17,18]. In the aftermath of these early findings, the current work aims primarily
disclosing the mechanisms by which proteins in Eulalia’s secretions become cytotoxic to
normal and cancer human cells, with the ultimate goal of asserting their biotechnological
potential. To meet our objectives, we isolated proteins from secretions and combined
proteomics with transcriptomics for their identification as a means to circumvent the
challenges of investigating a complex mixture of proteinaceous compounds and provide
inter-validation in a scenario of low genomic resources. The purified extracts were then
tested onto both normal and cancer humans cell lines.
2. Results
2.1. Protein Identification
Five major proteins were conclusively identified in Eulalia sp. mucosecretions by
superimposing proteomics and transcriptomics (Table 1 and Figure S1 in Supplementary
Information). The results identified arylsulfatase B (ARSB), heat shock protein 70 KDa
(HSP70), 14-3-3 protein, RAB3 and serine protease (SP) as the main proteins in extracts.
When comparing the relative expression of these proteins in the proboscis and body wall,
serine protease is the protein with higher expression in the proboscis, followed by ARSB,
RAB3 and lastly HSP70 and 14-3-3 protein. The peptide sequences had a 100% match with
the translated mRNAs, with the exception of SP, which yielded multiple transcriptional
variants (Figure S2).
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Table 1. Matched peptidic sequences and translated mRNAs upregulated in the proboscis and respective contrasting against
Pfam and Toxins databases.
Protein Method logFC Conserved Domain (Pfam) Protein Match e-Value (Blastp)
SP RNAseq 11.85 Trypsin-like serine protease Serine protease 33-like (Orbicella faveolata) 6 × 10−54
MS/MS - Serine protease (Protobothrops flavoviridis) 6 × 10−5
MS/MS - Transmembrane protease serine 7 (Ophiophagus hannah) 7.8
ARSB RNAseq 5.08 ALP P like superfamily Arylsulfatase B (Penaeus vannamei) 2 × 10−83
MS/MS - N-acetylgalactosamine 6-sulfate sulfatase (CandidatusMoranbacteria bacterium) 19
RAB3 RNAseq 3.96 Rab GTPase family 3 Rab3 (Doryteuthis pealeii) 2.00 × 10−147
MS/MS Rab GTPase family 3 Ras family protein (Trichuris suis) 1.00 × 10−06
MS/MS - Ras-related protein Rab-3 (Melipona quadrifasciata) 0.45
14-3-3 RNAseq 1.53 14-3-3 superfamily 14-3-3 zeta (Pristionchus pacificus) (38kDa) 2.00 × 10−121
MS/MS - 14-3-3-like protein 4 (Pseudotsuga menziesii) 0.21
HSP70 RNAseq 1.09 Heat shock 70 kDa protein HSPA8 protein (Homo sapiens) 0
MS/MS HSP70 Heat shock cognate 71 kDa protein (Cricetulus griseus) 3.00 × 10−15
2.2. Cytotoxic Effects
The purified extract caused higher antiproliferative effect towards MCF7 and espe-
cially A2780 cancer cell lines, compared to normal human primary fibroblasts (Figure 1,
Table 2). Most cancer cells presented a loss of cell viability when exposed to the concen-
tration of the extract within the range of 0.19 to 0.42 µg. µL−1, with the exception of the
ovarian carcinoma cell line (A2780), which yielded an IC50 value one order of magnitude
lower (0.08 µg. µL−1). Consequently, the ovarian carcinoma cancer cell line was then cho-
sen for further biological characterization towards addressing the mechanisms underlying
the loss of A2780 cell viability.
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A549 (F) cell lines. Cells were exposed for 48 h to purified proteins extracts corresponding to concentrations between 
Figure 1. Cell viability determined by the MTS assay in HCT116 (A), Fibroblasts (B), A2780 (C), K562 (D), MCF7 (E) and
A549 (F) cell lines. Cells were exposed for 48 h to purified proteins extracts corresponding to concentrations between
0.0022 and 1.6 µg. µL−1, plus controls (PBS only). Measurements are indicated as means ± SD of three independent
replicates. A positive control (doxorubicin) was used in all assays.
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Table 2. Half maximal inhibitory concentration (IC50) determined through the cell viability assay
(MTS assay). Values for the IC50 determined for each cell line are indicated as means ± SEE of three
independent replicates.
Cells IC50 ± SEE (µg. µL−1)
A2780 0.08 ± 0.01
HCT116 0.24 ± 4.00
A549 0.46 ± 0.05
MCF7 0.15 ± 0.04
K562 0.37 ± 0.04
Fibroblasts 0.29 ± 0.02
The frequency of apoptotic A2780 cells approximately doubled at IC50 concentrations,
for both 24 h and 48 h (Figure 2). However, after 12 h, no significant differences were found
when the cells were subjected to lower concentrations. Since apoptosis accounted only
for a maximum of 35% cell death, an additional mechanism of programmed cell death,
namely via autophagy, was assessed (Figure 3). Interestingly, a significant increase in
autophagic cell death was observed after 12, 24 and 48 h of exposure. To further con-
firm the induction of programmed cell death TEM analyses were performed (Figure 4).
Apoptotic bodies were easily noticed as early as 1 and 3 h of exposure, as well as chromatin
condensation and nuclear fragmentation by blebbing, in accordance with Hoechst la-
belling (Figure 2). Moreover, autophagolysosomes, associated with the autophagic process,
were noticed, especially after 24 h, also supporting the previous fluorescence microscopy
results (Figure 3). Exposure to higher concentrations (IC50), revealed further cellular alter-
ations, namely mitochondrial shape changes, nuclear pleomorphisms and an increase in
lysosome number.
For further clarification of the mechanism underlying apoptosis induction, the expres-
sion of BAX and BCL-2, the production of ROS, the mitochondrial membrane potential
(∆Ψm) and the induction caspase 8 were analyzed in A2780 cells exposed to the IC50 of
extracts. The low BAX/BCL-2 expression ratio (Figure 5A,B), the absence of ROS produc-
tion and the unchangeable ∆Ψm in A2780 cells exposed to the IC50 concentration of the
extracts (Figure S2), and the significant induction of caspase 8 activity (Figure 5C) clearly
suggests the activation of the extrinsic apoptotic pathway via activation of death receptors.
However, alterations to plasma membrane potential (∆Ψp) were noticeable after 1 h and 3 h
of exposure, as determined by flow cytometry and fluorescence microscopy (Figure 6A,B).
The effect of the extracts in A2780 cell-cycle progression was evaluated over time of
exposure (Figure 7). Cell-cycle arrest at phase S was observed 2 h after exposure (Figure 7B),
becoming significant after 3 h and 4 h exposure (Figure 7C,D). A slight delay in the
percentage of cells entering G2/M phase was also verified after 2 h exposure and extended
until 4 h exposure. Alterations in tubulin were also seen with immunohistochemical
staining after 3 h exposure. After 4 h exposure, an overcompensation of cells in the phase
G2/M started to be noticed, specially at 12 h exposure (Figure 7F). The changes in the
early hours were consistent with quantification of both β-actin at 1 h and α-tubulin at 3 h
(Figure 6C–F).
2.3. Network Analysis
The interaction between the human homologs of the main proteins present in ex-
tracts is depicted in Figure 8. The first network yielded interaction between 14-3-3 zeta
protein (YWHAZ), heat shock cognate 71 kDa protein (HSPA8) and Ras-related protein
Rab-3C (RAB3C). YWHAZ and HSPA8 yielded the strongest connection with reports of
co-expression in humans and other mammals. HSPA8 and RAB3C were also interacting
indirectly, trough cell division cycle 5-like protein (CDC5L), a DNA-binding protein in-
volved in cell-cycle control. The connection of HSPA8 and RAB3C and CDC5L have been
both supported by experimental data. HSPA8 and CDC5L were also connected with the
spliceosome-associated protein CWC15 homolog (CWC15) and Pre-mRNA-splicing factor
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SPF27 (BCAS2), important proteins that are involved in the spliceosome as well. Due to the
lack of direct interactions between PRSS1 and ARSB with the remaining proteins and each
other, the radius of the network was expanded to ten proteins. Individually, ARSB is inter-
acting mostly with glycoside hydrolase domain-containing proteins (IDUA, GUSB) and
with enzymes responsible for catalyzing the hydrolase of sulphate esters (SUMF1 and 2),
while PRSS1 only interacts with keratin (KRT10).




Figure 2. Determination of apoptosis in the A2780 cell line exposed for 12 h (A) and 24 h (B) to purified extracts corre-
sponding to the IC50 threshold (0.08 µg. µL−1) and exposed for 48 h (C) between 1/10 IC50 (0.08 µg. µL−1) and IC50. Blue 
arrows are indicative of normal nuclei and white arrows of apoptotic nuclei. Results are presented as mean ± SEM of three 
independent replicates. *Indicates significant differences towards control (Student’s t test, p < 0.01). Different letters are 
indicative of significant differences (Dunn’s test, p < 0.05). Scale bars: 10 µm. 
Figure 2. Determination of apoptosis in the A2780 cell line exposed for 12 h (A) and 24 h (B) to purified extracts corre-
sponding to the IC50 threshold (0.08 µg. µL−1) and exposed for 48 h (C) between 1/10 IC50 (0.08 µg. µL−1) and IC50.
Blue arrows are indicative of normal nuclei and white arrows of apoptotic nuclei. Results are presented as mean ± SEM of
three independent replicates. *Indicates significant differences towards control (Student’s t test, p < 0.01). Different letters
are indicative of significant differences (Dunn’s test, p < 0.05). Scale bars: 10 µm.
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mitochondria, regardless of apoptotic or autophagic cells, when compared with controls. Inset: membrane detail of cells
exposed to IC50 dosage during 48 h. Nuclei (n). Scale bars: 2 µm.
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control. Results are presented as mean ± SEM of three independent replicates. * Indicates significant differences to control
(Kruskal–Wallis H, p < 0.05).
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Figure 6. Plasmatic membrane potential (A, B) and fluorescent staining assays (propidium iodide for nucleic acid staining
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and 48 h (H), for A2780 cell line exposed to the extract (IC50, 0.08 µg. µL−1) and the respective control (PBS). The cell cycle 
was analyzed by flow cytometry. The cells for the immunofluorescent assay were probed with F-actin (green) and α-
tubulin (red) and counterstained with Hoechst dye 33258 (blue). Results are presented as mean ± SEM of three independent 
replicates. * Indicates significant differences to control (Student’s t-test, p < 0.05). ▪ Indicates differences to control (p < 0.1). 
Scale bars: 10 µm. 
  
i r 7. ell-cycle analysis and immunofluorescence assay at 1 h (A), 2 h (B), 3 h (C), 4 h (D), 9 h (E), 12 h (F), 24 h (G) and
48 h (H), for A2780 cell line exposed to the extract (IC50, 0.08 µg. µL−1) and the respective contr l (PBS). The cell cycle was
an lyzed by flow cytometry. The cells for the immunofluorescent assay were probed with F-actin (gree ) and α-tubulin
(red) and counterstained with Hoechst dye 33258 (blue). Results are presented as mean ± SEM of three independent
replicates. * Indicates significant differences to control (Student’s t-test, p < 0.05). Indicates differences to control (p < 0.1).
Scale bars: 10 µm.
Mar. Drugs 2021, 19, 31 10 of 22
Mar. Drugs 2021, 19, x FOR PEER REVIEW 10 of 23 
 
 
2.3. Network Analysis 
The interaction between the human homologs of the main proteins present in extracts 
is depicted in Figure 8. The first network yielded interaction between 14-3-3 zeta protein 
(YWHAZ), heat shock cognate 71 kDa protein (HSPA8) and Ras-related protein Rab-3C 
(RAB3C). YWHAZ and HSPA8 yielded the strongest connection with reports of co-ex-
pression in humans and other mammals. HSPA8 and RAB3C were also interacting indi-
rectly, trough cell division cycle 5-like protein (CDC5L), a DNA-binding protein involved 
in cell-cycle control. The connection of HSPA8 and RAB3C and CDC5L have been both 
supported by experimental data. HSPA8 and CDC5L were also connected with the 
spliceosome-associated protein CWC15 homolog (CWC15) and Pre-mRNA-splicing fac-
tor SPF27 (BCAS2), important proteins that are involved in the spliceosome as well. Due 
to the lack of direct interactions between PRSS1 and ARSB with the remaining proteins 
and each other, the radius of the network was expanded to ten proteins. Individually, 
ARSB is interacting mostly with glycoside hydrolase domain-containing proteins (IDUA, 
GUSB) and with enzymes responsible for catalyzing the hydrolase of sulphate esters 
(SUMF1 and 2), while PRSS1 only interacts with keratin (KRT10). 
 
Figure 8. A network analysis between human protein homologs (HSPA8, RAB3C, YWHAZ, ARSB and PRSS1) using 
STRING. The two autonomous protein interaction networks were expanded to allocate additional ten proteins to increase 
the radius of interactions beyond the proteins identified in the present work. (A) Network with the homologs HSPA8, 
RAB3C, YWAZ and their respective interactions. (B) Network with the homologs ARSB, PRSS1 and their respective inter-
actions. The confidence cut-off for showing interaction links has been set to medium (0.400). ARSB—arylsulfatase B; 
Figure 8. A network analysis between human protein homologs (HSPA8, RAB3C, YWHAZ, ARSB and PRSS1) using
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RAB3C, YWAZ and their respective interactions. (B) Network with the homologs ARSB, PRSS1 and their respective
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BAG1—BCL-2 associated athanogene family molecular chaperone regulator 1; BCAS2—Pre-mRNA-splicing factor SPF27;
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HSPA8—heat shock cognate 71 kDa protein; HSP90AA1—heat shock protein HSP 90-alpha; HSP90AB1—heat shock protein
HSP 90-beta; IDUA—alpha-L-iduronidase; KRT10—keratin, type I cytoskeletal 10; PRSS1—trypsin-1; RAB3C—Ras-related
protein Rab-3C; RAF1—RAF proto-oncogene serine/threonine-protein kinase; SUMF1—sulfatase-modifying factor 1;
SUMF2—sulfatase-modifying factor 2; YWHAB—14-3-3 protein beta/alpha; YWHAZ—14-3-3 protein zeta.
3. Discussion
The mucus secreted by the marine worm Eulalia contains a mixture of toxin and non-
toxin proteins involved in multiple functions for attacking prey and defense against preda-
tors and environmental variables (as described in the present work and in Rodrigo et al. [19]).
This cocktail of proteins revealed higher toxicity towards the A2780 ovarian cancer cell line,
compared to other human cancer cells and even normal fibroblasts, with a strong indi-
cation for a dose- and time-dependent responsiveness. We hypothesized that combining
proteomics with transcriptomics would shed light on the main proteins involved in cyto-
toxicity and offer insights on their mode-of-action against A2780 cells, which is seemingly
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associated to cell-cycle arrest and the induction of programmed cell via extrinsic apoptosis
and autophagy. Five proteins were cross-validated by RNA-Seq, whose function, isolated
or combined, are responsible for the specific effects in A2780 cells.
The cytolytic properties of animal venoms, poisons and toxungens toward cancer cells
has been investigated with promising results, albeit scant comparisons between the differ-
ential effects against normal and cancer cells. Bee venom has arguably become one of the
most studied and promising cases, with melittin (a 26-amino acid lytic peptide responsible
for the painful sting) and phospholipase A being, so far, pinpointed as key substances
involved in the promotion of apoptosis [20]. Venoms from snakes also received attention,
in research with cancer cell lines inclusively [21–23]. For example, crude venom samples
from Naja ashei induced cell-cycle arrest and promoted apoptosis with the activation of
Caspase 3 and 9 in colorectal carcinoma (HCT116) cells [24]. Additionally, venoms from
spiders showed high cytotoxic activity towards K+ channels expressing cancer cells [25].
Nonetheless, a paramount aspect retrieved from the current findings is the differential
cytotoxic effects of the toxin mixture onto different cell cultures, with emphasis on higher
sensitivity of A2780 comparatively to normal primary fibroblasts and other cancer cells.
The results indicate that the activation of cell proliferation and cell cycle control pathways
can be cell type-specific and therefore that the combined effect of toxin proteins act upon
such pathways that are more significantly activated in A2780, such as those based on the
interplay between BCL-2 and HSP70.
From the five proteins identified from Eulalia mucus secretions, arylsulfatase B (ARSB)
and serine proteases (SP) are commonly found in venoms [26–28]. Sulfatases are known to
play a key role in the control of physiological processes like cell signaling, hormone regu-
lation and degradation of complex macromolecules such as glycosaminoglycans [29–31].
Arylsulfatase B, specifically, is known to regulate the kininogen–bradykinin axis trough the
effect on chondroitin-4-sulfation and the interaction of C4S with kininogen in rat kidney
epithelial cells, influencing blood pressure in mammals [32]. In lymphocytes, arylsulfatase
may function in the degradation of cerebroside sulphate ester components of the target cell
membrane to initiate the lytic event, having an important role in the immune response [33].
In mollusks, it can function as a sulphur-scavenging enzyme, which may play a role in
the breakdown of sulphated saponins [28]. The exact function of arylsulfatases in toxic
secretions are still unknown, even though this enzyme exists at high quantities in a broad
range of organisms, from snakes to predatorial gastropods [27,34]. In turn, serine proteases
form one of the largest group of endopeptidases. They are involved in a wide range of
physiological processes, from digestion to blood coagulation, fibrinolysis, development,
fertilization, apoptosis and play an immunity role as well [35]. In venoms, serine proteases
are present in a wide span of animals as well, being well described in snakes and bees.
These proteases have thrombin-like effects, promote fibrinogen degradation in prey and
activate the phenoloxidase cascade that induces a lethal melanization response in insects
attacking bees and their hives [36–38].
Other proteins in the toxungenous cocktail of Eulalia are not commonly associated
with venoms, poisons or toxungens. However, they play paramount roles in cell home-
ostasis. It is the case of heat shock proteins (HSP). Heat shock protein 70 KDa (HSP70) is
usually involved in stress response, helping protein folding (assembly and refolding) in the
endoplasmic reticulum [39]. In turn, RAB3C is located in synaptic and secretory vesicles
and regulates exocytosis Ca2+-dependent secretion and vesicle docking, thus being essen-
tial in exocytic and endocytic membrane trafficking [40,41]. The RAB3C protein can also be
linked with ZW10-interacting protein 1 (Zwint-1), a protein implicated in the regulation of
chromosomal segregation through binding to the kinetochore [42]. The gene encoding this
protein, ZWINT, was discovered to be overexpressed in ovarian cancer, among other genes
(such as CCNB1, CENPF, KIF11) related with cell cycle, nuclear division and oocyte meio-
sis [43]. The 14-3-3 protein plays a role in various cellular processes like signal transduction,
cell-cycle regulation, apoptosis, stress response, cytoskeleton organization and malignant
transformation [44]. It must be noted, though, that other proteins may either have not
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been identified by cross-validation between MS/MS on mucus secretions and skin whole-
transcriptome analyses. We must, at this stage, highlight difficulties in homology-based
identification of peptides from organisms with reduced genomic annotation. Even though
the purification process can, itself, be responsible for the loss of proteins, the toxicological
appraisal of the purified extracts does indicate that the active components that yielded
effects against A2780 cells were not lost.
The identified proteins, when integrated within protein interaction networks (Figure 8),
suggest a potential combined effect. Nonetheless, there are seemingly two pathways:
one involving HSPs, 14-3-3 protein and RAB3C, and another where ARSB is pivotal.
In the first pathway, 14-3-3 can be the key component, as these proteins are known to
play a part in apoptosis and cell-cycle arrest. However, different 14-3-3 isoforms may
produce distinct outcomes [44]. Still, the protein here identified holds higher similarities
to 14-3-3 protein zeta (YWHAZ), which suggests promotion of programmed cell death.
However, some isoforms may have indirect association with BAG1, which may in turn
bind to BCL-2 and promote cell survival. It is also able to bind to the serine/threonine-
specific protein kinase RAF1 and stimulate RAF1 kinase activity. Moreover, BAG1 also
binds to the chaperone HSP70 (HSPA8), being, in fact, a possible chaperone inhibitor [45].
Speculations have been made to whether BCL-2 is able to form channels to transport
proteins through membranes and if HSP70 unfolds proteins during such transport [45,46].
In any case, the formation of these channels may contribute to explain BCL-2 overexpression
(Figure 5A). At the same time membrane integrity may be compromised by other proteins
in the cocktail, explaining the changes in plasmatic membrane potential from 1 h of
exposure (recall Figure 6A,B), then likely triggering a series of events that may ultimately
lead to cell-cycle arrest and cell death.
The RAF proto-oncogene identified in the network is responsible for the regulation
of many fundamental cell processes, including proliferation, differentiation, apoptosis,
motility and metabolism [47]. The activation of this protein and the mitogen-activated
protein kinase (MAPK) pathway is dependent of proteins present in the network such as
HSPA8, HSP90 and CDC protein. These proteins were found to be crucial for the maturation
and activation of RAF1 both in Drosophila and human cell lines [48,49]. RAF1 activity
is also regulated by 14-3-3 proteins, trough phosphorylation, to control its enzymatic
activity [50]. The CDC protein is directly connected with CWC15 and BCAS2, both involved
in the regulation of gene expression, and is an essential regulator that activates cyclin-
dependent kinases (CDKs) at critical stages of the cell cycle [51]. The disruption of the
regulatory function can lead to cell-cycle arrest and autophagy, which are the mechanisms
by which A2780 cells were affected. More specifically, the 14-3-3 protein present in the
extract may well be, directly or indirectly, keeping the cyclin-dependent kinase CDC2
(cell division control protein 2) inactive, thereby preventing G2 to M transition [44,52],
as seen in A2780 cells between 2 h to 4 h of exposure (Figure 6). The RAB3C protein is
also responsible for cell-cycle arrest through binding to ZW10-interacting protein 1 [42,43].
Additionally, cell-cycle arrest in the S phase is also connected with the depolarization of
the resting membrane potential [53], which is in accordance with our results after 3 and 4 h
of exposure. After 9 h exposure to the cocktail, cell-cycle progression was promoted when
the assays were extended until 48 h. This effect was not, however, sufficient to avoid loss
of cell viability.
Heat shock proteins 70 controls many housekeeping processes [54], which is probably
the reason why HSPA8 one of their forms, is linked directly with almost all proteins in the
network (except RAB3C) described in Figure 8. Two of these interplays occur with other
chaperones, namely HSP90 alpha and beta. Besides interfering with cell-cycle progression,
HPSs can also be involved in the activation of matrix metalloproteinases. In fact, it has
been seen that extracellular HSP90 alpha in fibrosarcoma and breast cancer cells promote
MMP2 activation, which is critical for tumor invasiveness [55]. In turn, nuclear HSP70
promotes aurora kinase B (AURKB) activity, which is normally dysregulated in cancer cell
lines [56].
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Other homologs from known toxins (PRSS1 and ARSB) appeared, at first sight, to have
a smaller contribution to the effects seen in A2780. However, ARSB is known to have its
expression reduced in most carcinomas when compared with normal tissues [57]. However,
as the authors refer, there are some cases of cancer cells where arylsulfatases (ARS) are
overexpressed (ARSA and ARSB), as in human lung cancer, pertaining to one of the cell
lines tested that yielded lower toxicity of extracts, comparatively to fibroblasts. The overall
reduction in the expression of ARS was found to be related to prostate cancer aggres-
siveness, due to the association between ARSB and the epidermal growth factor receptor
(EGFR), commonly overexpressed when ARSB is reduced [58,59]. The EGFR has a crucial
role in cell differentiation and proliferation and cancer, being ARSB regulation an important
target for cancer therapy [59].
Finally, it must be noted that the co-occurrence of apoptosis and cell death by au-
tophagy has already been reported in A2780 cells exposed, e.g., to metal-based com-
pounds [1,60,61]. Both pathways, occurring simultaneously, were also reported in a cervical
cancer cell line, where the accumulation of autophagic vacuoles preceded the apoptotic
cell death [62]. However, all the studies have been performed with isolated compounds,
while the present study dealt with a mixture of proteins, leading to complex interactions
and likely intricate downstream effects on cell homeostasis. Even though the combined
effect of toxins secreted by marine invertebrates has received little attention, there are
indications that venomous mixtures are more effective against human cancer cells than
individualized components, such as in a recent study with glycoconjugates extracted from
a starfish tested on colorectal carcinoma cells [63].
4. Materials and Methods
4.1. Protein Extraction and Identification
4.1.1. Animal Collection
Adult Eulalia sp. (≈120 mm total length and weighting ≈250 mg each) were collected
from the West Coast of Portugal (38◦41′42′′ N, 09◦21′36′′ W), in an intertidal rocky beach.
Animals were reared in the laboratory in a mesocosm environment recreating their natural
habitat, with controlled salinity, temperature and photoperiod (35 ± 1, 16 ± 1 ◦C and
10:16 h, respectively). Animals were fed with live mussels, one of the species’ favorite prey.
4.1.2. Protein Collection and Purification
Protein was collected from mucous secretions harvested non-invasively by placing
the worms in microfuge tubes with filtered sterile seawater, followed by mechanical
stimulation of the proboscis, leading to increased secretion. Crude protein extracts were
obtained from approximately fifty animals per pool. The crude extracts were immediately
diluted ≈ 1:1 in 0.05 M Tris-HCl containing 10% (w/v) L-dithiothreitol (DTT) and 1%
(v/v) protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Samples were then
filtered through a syringe cellulose acetate filter (0.22 µm). Purification and concentration
of extracts was done by dialysis (ultrafiltration) using 3kDa Amicon Ultra centrifugal filters
(Merck, Algés, Portugal), with Dulbecco’s phosphate-buffered saline (DPBS, pH 7.4) as the
vehicle. Total protein content was determined using a Nanodrop 1000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA). Purified extracts were stored at −80 ◦C
until further analyses.
4.1.3. Protein Separation
Proteomics was employed to analyze the purified protein extracts using either, one- or
two-dimensional gel electrophoresis (1DE and 2DE, respectively) for initial separation [64].
The Laemmli discontinuous gel of Laemmli [65] was used for 1DE separation by sodium
dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE), as detailed by Hames [66].
Stacking and running gels (8 × 9 cm by 0.75 mm thick) contained 12% (v/v) and 6% (v/v)
acrylamide, respectively. The migration buffer consisted of 25 mM Tris, 192 mM glycine,
pH 8.5. Molecular standards (NZYColour Protein Marker II range 11-245 kDa) was pur-
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chased from Nzytech. The 2-D separation was obtained by isoelectric focusing (IEF)
followed by SDS-PAGE. Briefly, the sample consisted of 100 µL of purified protein extract
treated with 2-D Clean-Up Kit (GE Healthcare, Chicago, IL, USA), according to manu-
facturer’s instructions. Precipitated proteins were resuspended in 100 µL of rehydration
solution containing 4% (w/v) CHAPS, 7 M urea, 2 M thiourea, 1% (w/v) DTT GE Healthcare,
0.5% (v/v) Immobilized pH Gradient buffer (GE Healthcare) and 0.002% (w/v) bromophe-
nol blue, and incubated at room temperature for 36 h. After protein quantification using
the Pierce 660 nm protein assay reagent (Thermo Fisher Scientific, Waltham, MA, USA),
125 µL of rehydration buffer containing 200 µg of protein were applied onto Immobiline
Drystrip IPG strips (GE Healthcare) with 7 cm and 3± 10 non-linear pH. After rehydration,
Isoelectric focusing (IEF) was done in an Ettan IPGphor instrument (GE Healthcare) at
a maximum voltage of 5000 V. The IPG strips were afterwards incubated for 15 min in
equilibration buffer 1 (50 mM Tris-HCl pH 8.8, 2% (w/v) SDS, 6 M urea, 30% (v/v) glycerol,
1% (w/v) DTT, followed by incubation for another 15 min in equilibration buffer 2 (50 mM
Tris-HCl pH 8.8, 2% (w/v) SDS, 6 M urea, 30% (v/v) glycerol, 2.5% (w/v) iodoacetamide).
Strips were then placed on top of a 10% SDS-PAGE gel for separation by mass. Both gels
were stained with Coomassie Brilliant Blue G-250 to identify most representative spots
and bands (Figure S1) to be picked for liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) analyses. Excised gel bands and spots were stored at −80 ◦C
until further processing.
4.1.4. Protein Identification by LC-MS/MS
After gel sample destaining and digestion with porcine trypsin, peptides were ana-
lyzed on a Eksigent NanoLC Ultra 2D separation system coupled to a TripleTOF 6600 mass
spectrometer, all from Sciex (Framingham, MA, USA). The chromatographic separation
by micro-LC was achieved in a ChromXP C18CL column (0.3 × 150 mm, 3 µm, 120 Å,
from Eksigent), at 50 ◦C. The flow rate was set to 5 µL/min and mobile phase A and B
were 0.1% (v/v) formic acid plus 5% (v/v) DMSO in water and 0.1% (v/v) formic acid plus
5% (v/v) DMSO in acetonitrile, respectively. The ESI DuoSprayTM ionization source was
operated in the positive mode set to an ion spray voltage of 5500 V, 25 psi for nebulizer
gas 1 (GS1), 25 psi for the curtain gas (CUR). The rolling collision was used with a colli-
sion energy spread of 5. Peptide mass fingerprinting was performed using ProteinPilot
5.0.1 (Sciex) considering the following parameters: cysteine alkylation by acrylamide,
digestion by trypsin, and gel-based ID as a special factor. The resulting amino acid
sequences were contrasted against UniProtKB and NCBInr databases using Blast [67].
Accuracy of identification was determined by the lowest e-values and number of matching
peptides per protein.
4.1.5. Protein Identification by RNA-Seq
The peptide sequences were contrasted against Eulalia sp. proboscis transcriptome [19],
deposited in Gene Expression Omnibus (GEO) under the accession number GSE143954
(Figure S2). The results from RNASeq were validated by RT-qPCR. In brief: cDNA was syn-
thesized from the total RNA samples using the First-Strand cDNA Synthesis Kit (NZYTech).
Primers were designed using Primer Blast and verified in silico with Oligo Analyzer
(Table S1) to amplify an expressed sequence tag (EST) for mRNAs coding for proteins
identified by MS/MS and RNA-Seq. The calibrator was GAPDH, as suggested [68].
Amplification was done in a Biometra Gradient Thermocycler96. Following resolving
PCR products in an agarose gel, these were Sanger-sequenced (as a service), translated
and matched against (1) UNIPROT cluster UniRef90 [69] by generating a customized toxin
database, with BLASTP v2.5.0 [70], having set a maximum e-value of 10−5; (2) NCBInr
using BlastP. The RT-qPCR was then done in a Rotor-Gene 6000 thermal cycler (Corbett
Research) using the NZY qPCR Green Master Mix (NZYTech), according to manufacturer
instructions. The program was set as: denaturation 94 ◦C, 45 s (s), annealing 55 ◦C, 25 s and
extension 72 ◦C, 30 s, with 45 cycles per run. Primer melting analysis was also conducted to
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verify the specificity of hybridization. Relative expression was determined by the 2−∆∆Ct
method [71].
4.2. Network Analysis
After the identification of the main proteins by combining proteomics and transcrip-
tomics, Homo sapiens homologues were retrieved using BLASTP. Gene network analyses
were conducted using the Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING) by setting the confidence cut-off for interaction links between proteins at
0.400 [72].
4.3. Cell-Based Assays
HCT116 (human colorectal carcinoma), A549 (lung adenocarcinoma), human primary
fibroblasts, MCF7 (breast carcinoma) and K562 (myelogenic leukemic carcinoma) cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Grand Island, NY,
USA) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) antibiotic/antimycotic
solution (Invitrogen), while A2780 (ovarian carcinoma) cells were grown in modified
McCoy’s medium: Roswell Park Memorial Institute medium (RPMI) 1630 [73,74]. All cell
lines were purchased from ATCC (http://www.atcc.org) with the exception of A2780
that was purchased from Sigma-Aldrich. All cell cultures were maintained at 37 ◦C in a
humidified atmosphere containing 5% (v/v) CO2 and incubated in the same atmosphere
when necessary. Only purified extracts stored for less than 30 days (−80 ◦C) were used in
biological assays and all dilutions (and controls) were prepared in PBS. The same volume
of PBS was added to the respective medium of each assay (controls). Total protein content
was determined prior to biological assays using a Nanodrop spectrophotometer (Thermo
Fisher Scientific). The assays were conducted with cells seeded for 24 h and in the range of
105 cells. mL−1, in the conditions described before, in 6, 24 or 96-well plates, depending on
the endpoint.
4.3.1. Cell Viability
Cell viability was determined by subjecting all cell lineages to successive dilutions
of the purified protein extract (2 × 10-3 to 1.6 µg. µL−1) for the estimation of the half-
maximal inhibitory concentration (IC50). Cells were incubated for 48 h with each diluted
extract. Viability was determined with the CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay (Promega, Madison, WI, USA), using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt (MTS). Quantification
of the formazan dye formed in viable cells was done spectrophotometrically by measuring
absorbance at 490 nm with a Bio-Rad microplate reader Model 680 (Bio-Rad, Hercules,
CA, USA) [73–75]. The assays were performed in triplicate and technical duplicates were
included, to minimize technical error. Doxorubicin (0.4 mM) was used as a positive control
in all assays.
4.3.2. Apoptosis
Apoptosis was determined based on the Hoechst 33258 labelling assay. Cells were
seeded on sterilized coverslips and incubated for 24 h to obtain an adherent monolayer.
Cells were then incubated with the purified extract for 12 h (IC50), 24 h (IC50) and 48 h
(1/10 IC50, 1/5 IC50 and IC50). After incubation, cells were washed with PBS and fixed
with fresh 4% (m/v) formaldehyde (reconstituted from paraformaldehyde), for 10 min in
the dark. Cells were then incubated with the dye (provided by Sigma-Aldrich), prepared as
5 µg. mL−1 in PBS. After 10 min, slides were washed with PBS and mounted. Fluorescent
nuclei (100 per sample) were sorted in a DM 2500 LED model microscope, adapted for epi-
fluorescence with an external EL6000 light source (Leica Microsystems, Wetzlar, Germany).
The assay was performed in triplicate for each timeline. The results are expressed as the
mean percentage of apoptotic nuclei.
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4.3.3. Autophagy
Cells were exposed to the extracts for 12 h, 24 h and 48 h, at the same concentrations
than the previous assay. Rapamycin (50 mM) was used as a positive control [61,74]. By the
end of each assay, the medium was removed, and cells were stained with the CYTO-ID Au-
tophagy Detection Kit (ENZO, New York, NY, USA), following manufacturer instructions.
Stained cells were imaged with the aforementioned epifluorescence microscope following
counterstaining with DAPI. The assay was performed in triplicate for each timeline.
4.3.4. Caspase 8 Assay
The activity of Caspase 8 was determined to assess the extrinsic apoptotic pathway
using the Caspase 8 assay kit from Abcam, following manufacturer instructions. Briefly,
cells were plated on T-flasks with an area of 25 cm2 with 6 × 105 cells. mL−1 for 24 h
and exposed to the purified extract (IC50 dose), plus PBS (control) and incubated for 48 h.
Cells were then scraped, washed in PBS, resuspended in cell lysis buffer and incubated
on ice for 30 min. Total protein in lysates was quantified as previous and adjusted to
200 µg/50 µL buffer. Each microplate well was loaded with 200 µg protein/50 µL 50 µL of
2× Reaction Buffer with DTT (100 mM final concentration) and 5 µL of IETD-pNA substrate
(4 M). After incubation (2 h), absorption at 400 nm was quantified on a 680 Microplate
Reader (Bio-Rad, Hercules, CA, USA).
4.3.5. Detection of Reactive Oxygen Species
Intracellular reactive oxygen species (ROS) were determined using the KITNAME
(Sigma-Aldrich), as previously described [1]. Briefly, cells were seeded and incubated for
24 h, after which the culture medium was removed and replaced by fresh medium contain-
ing 1/10 IC50, 1/5 IC50 and IC50 (0.08 µg. µL−1), plus controls. Hydrogen peroxide (50 µM)
was used as a positive control. Cells were harvested after 48 h, washed twice with PBS before
resuspension in pre-warmed (37 ◦C) PBS containing 100 µM 2,7-dichlorodihydrofluorescein
diacetate (H2DCF-DA) and incubation at 37 ◦C for 20 min, in the dark. Fluorescence
intensity was measured on an Eclipse Ti inverted microscope equipped with a DS-QiMc
camera and adapted for epifluorescence (all from Nikon), with fixed exposure time for all
samples. The green fluorescent signal was normalized and analyzed using ImageJ [76].
4.3.6. Mitochondrial Transmembrane Potential
The mitochondrial transmembrane potential was analyzed using the bis(5,6-dichloro-
1,3-diethyl-2-benzimidazole)trimethinecyanine iodide (JC-1) dye (Abnova Corporation,
Walnut, CA, USA). After seeding and incubation cells were treated with the protein extract
at the concentrations of 1/10 IC50, 1/5 IC50 and IC50 diluted in fresh medium and exposed
for 48 h. Cells were then stained with the JC-1 staining solution for 20 min at 37 ◦C in
the dark. Image acquisition and analysis was done as above, based the ration between
green and red fluorescence.
4.3.7. Plasmatic Transmembrane Potential
The plasmatic transmembrane potential was analyzed using 2′,7′-Bis(2-carboxyethyl)-
5(6)-carboxyfluorescein tetrakis(acetoxymethyl) ester (BCECF-AM) dye (Invitrogen).
After seeding and incubation, cells were treated with the purified protein extract at
the concentration of IC50, diluted in fresh medium (RPMI), and incubated for 1 h and
3 h. Cells were then trypsinized and washed with PBS and RPMI medium (without
phenol red) before incubation with BCECF-AM (2 µM in the same medium) for 20 min,
at 37 ◦C. After washing in the culture medium, data was collected using an Attune acoustic
focusing flow cytometer (ThermoFisher Scientific) and analyzed using FCS Express 6.0
Flow Cytometry (De Novo Software, Pasadena, CA, USA). The results were normalized
for cell counts and the respective control. The assays were performed in duplicate and
technical duplicates were included to minimize technical error. Doxorubicin (0.4 mM) was
used as a positive control in all assays.
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4.3.8. Interference of Cellular pH or Membrane Integrity
After seeding and incubation, cells were treated with the protein extract at the con-
centration of IC50 diluted in fresh RPMI medium for 1 and 3 h. After washing with RPMI
(without phenol red), cells were incubated with BCECF-AM (µM) for 20 min, washed again
and incubated with propidium iodide (2.5 µg. mL−1) for 10 min. Cells were then washed
and visualized in RPMI (without phenol red) under an Eclipse Ti fluorescence microscope,
equipped with a DS-QiMc camera (Nikon Instruments, Amsterdam, Netherlands).
4.3.9. Western-Blot
Cells were plated on T-flasks with an area of 75 cm2 with 4 × 105 cells. mL−1. After in-
cubation for 24 h to allow adhesion, cells were treated with fresh medium supplemented
with purified extract at the concentration of IC50 or PBS (control) and incubated for 48 h.
The cell monolayer was washed three times with PBS and the cells were detached by scrap-
ing. The cells were pelletized by centrifugation at 500× g for 5 min (4 ◦C). The following
procedure was adapted from Vinhas et al. [77], using a PVDF membrane (GE Healthcare).
Signal acquisition was obtained with Hyperfilm ECL (GE Healthcare). The protein band
intensities relative to controls was quantified using ImageJ [78] following normalization to
β-actin values.
4.3.10. Cell-Cycle Analysis
Cells were seeded in a 6-well plate at 1 × 105 cells per well and synchronized in early
S-phase using a thymidine double block [74]. After the second block, the medium was
replaced with fresh medium containing the extract or control (PBS only). The cells were
collected by trypsinization after 1 h, 2 h, 3 h, 4 h, 9 h and 24 h. After centrifugation at
650× g for 5 min at 4 ◦C, pelleted cells were washed with 1 mL cold PBS and centrifuged at
3000× g for 5 min at 4 ◦C. The cells were then suspended in 100 µL cold PBS and completely
disaggregated by soft pipetting before gently adding 1 mL ice-cold ethanol (80% (v/v)).
After at least 16 h at 4 ◦C, the cells were pelletized by centrifuging at 5000× g for 10 min
at 4 ◦C and the supernatant discarded. The cells were treated for 30 min with RNase A
50 µg. mL−1 at 37 ◦C and propidium iodide was added to a final concentration of 25 µg.
mL−1. Data was collected using an Attune acoustic focusing cytometer (ThermoFisher
Scientific) and analyzed using FCS Express 6 Flow Cytometry (De Novo Software).
4.3.11. Determination of Cytoskeletal Alterations
Cells were seeded for 24 h in 24-well plates at 1 × 105 cells. mL−1 for 3 h, 6 h and 12 h
and at 0.375 × 105 cells. mL−1 for 48 h. Cells were then fixed in 4% (v/v) formaldehyde,
permeabilized with 0.1% (v/v) Triton X-100 and blocked with 1% (w/v) bovine serum
albumin (BSA). The cells were probed with Alexa Fluor 488 Phalloidin (2.4% (v/v) in 1%
(w/v) BSA, 20 min) to stain actin filaments, followed by Hoechst 33258 (Sigma, Missouri,
USA) at 5 µg. mL−1 in PBS (15 min) as the nuclear counterstain. Alpha tubulin was tagged
with the DM1A anti-α-tubulin monoclonal antibody (Sigma-Aldrich), diluted to 1:200 in 1%
(w/v) BSA. After incubation o/n at 4 ◦C, the primary antibody was tagged with anti-mouse
TRITC-conjugated polyclonal secondary antibody (Sigma), diluted to 1:64 in 1% (w/v) BSA
(1 h). Cells were then washed with Tris-buffered saline (pH 7.6) with Tween 20 (TBST)
and mounted with PBS. The cells were then examined with an Eclipse Ti fluorescence
microscope (Nikon Instruments), as described previously.
4.3.12. Cytology
Cells, seeded in 24-well plates with a density of 106 cells. mL−1, were exposed to
different concentrations of the purified extract (IC50, 1/5 IC50, 1/10 IC50), plus controls
(PBS), for 48 h and additionally to IC50 for 1 h and 3 h. After exposure, cells were scraped
and processed for transmission electron microscopy (TEM) as described in Vogt et al. [79],
with modifications. Briefly, cells were fixed in 2.5% (v/v) glutaraldehyde in 0.1 M phosphate
buffer and post-fixed in 2% (w/v) osmium tetroxide in 0.1M phosphate buffer, overnight.
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Pellets were washed in ultrapure water and dehydrated in a progressive series of acetone.
Pelletized cells were embedded in Epon resin (Sigma-Aldrich) using propylene oxide as
intermediate. Thin sections (50–60 nm) were obtained with an Ultracut E ultramicrotome
Leica. Sections were collected onto copper and nickel mesh grids and contrasted with 2%
(w/v) aqueous Uranyl Acetate and Reynold’s Lead Citrate [80]. Grids were analyzed using
a JEOL 100-SX model TEM operated at 80 kV.
4.3.13. Statistical Analysis
The half maximum inhibitory concentration (IC50) was estimated using least squares
regression and the results are expressed as IC50 ± standard error of estimates (SEE).
Normality and homoscedasticity were evaluated using Shapiro-Wilk’s and Levene’s tests,
respectively. When assumptions were met for parametric analyses, we employed ANOVA
based on F and Dunn’s tests for multiple comparisons, otherwise the non-parametric
Kruskal–Wallis H statistic was used, followed by Student’s T-test and Mann-Whitney’s U
(parametric and non-parametric tests, respectively) for paired-sample tests. Statistics were
computed using R 3.5 [81]. The significant level was set at 0.05 for all the analyses.
5. Conclusions
In large part due to the number and variety of compounds therein, toxin-bearing
secretions of marine invertebrates may have cytotoxic properties beyond the functions
acquired by means of natural selection. The present study showed that proteins present in
the mucus secreted by a toxungenous marine worm, five of which were positively identified,
can specifically cause cell-cycle arrest by a mechanism that is specific to A2780 ovarian
adenocarcinoma cells among a panel of six human cell lines, normal included. Even though
the precise mechanisms still need further exploration, the effects on A2780 cells seem to
derive from the collision of two interaction networks: one centered in cell-cycle arrest as
a consequence of dysregulation of protein expression and folding, with a link to RAB3C
oncoprotein function; another centered in the lytic activity of arylsulfatases, common
enzymes in animal venoms and poisons. The mechanisms, however, are complex and
the exact quantities of each individual component in the extract may vary. Nevertheless,
the variation in this case seems to be neglectable, as the usage of biological replicates
gave similar results. Thus, the consistency of the findings supports the potential of mixed
proteins in venoms against aggressively-proliferating cells, as seen, e.g., for bee venoms,
steering toward a novel approach to anti-cancer treatments while highlighting the immense
potential of the oceans as a source of novel therapeutics.
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